Insmed Inc (INSM)vsScinai Immunotherapeutics Ltd (SCNI)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
SCNI
Scinai Immunotherapeutics Ltd
$0.67
-0.96%
HEALTHCARE · Cap: $2.17M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 52770% more annual revenue ($606.42M vs $1.15M). SCNI leads profitability with a 4.5% profit margin vs -2.1%. SCNI earns a higher WallStSmart Score of 61/100 (C+).
INSM
Hold39
out of 100
Grade: F
SCNI
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INSM.
Margin of Safety
+99.6%
Fair Value
$187.20
Current Price
$0.67
$186.53 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 36.1% year-over-year
Earnings expanding 87.2% YoY
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Smaller company, higher risk/reward
4.5% margin — thin
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : SCNI
The strongest argument for SCNI centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 36.1% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : SCNI
The primary concerns for SCNI are Market Cap, Profit Margin, Free Cash Flow. Thin 4.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while SCNI is a hypergrowth play — different risk/reward profiles.
SCNI carries more volatility with a beta of 1.90 — expect wider price swings.
SCNI is growing revenue faster at 36.1% — sustainability is the question.
SCNI generates stronger free cash flow (-1M), providing more financial flexibility.
Bottom Line
SCNI scores higher overall (61/100 vs 39/100) and 36.1% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Scinai Immunotherapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Scinai Immunotherapeutics Ltd is an innovative biotechnology firm at the forefront of developing advanced immunotherapy solutions, particularly targeting cancer and autoimmune disorders. Leveraging its proprietary immune modulation platform, Scinai is advancing a promising clinical pipeline designed to deliver transformative therapies that enhance patient outcomes. Guided by a seasoned leadership team with extensive expertise in immunology and drug development, the company is poised to capitalize on the burgeoning demand for groundbreaking immunotherapeutics in the global healthcare market. Scinai's commitment to rigorous research and strategic partnerships further positions it for significant growth and impact within the biopharmaceutical industry.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?